Document is current
Any future updates will be listed below
-
Authors
Fucà, Giovanni
Fabbroni, Chiara
Mancari, Rosanna
Manglaviti, Sara
Bogani, Giorgio
Fumagalli, Elena
Bertulli, Rossella
Morosi, Carlo
Collini, Paola
Raspagliesi, Francesco
Colombo, Nicoletta
Casali, Paolo G.
Sanfilippo, Roberta
- License Information
-
More Information
Article History
Received: 13 March 2020
Accepted: 17 August 2020
First Online: 28 August 2020
Ethics approval and consent to participate
: The study was approved by the Institutional Review Boards of Fondazione IRCCS Istituto Nazionale dei Tumori di Milano and European Institute of Oncology and was conducted according to the ethical principles for medical research involving human subjects adopted in the Declaration of Helsinki. All the patients signed an informed consent for the use of their clinico-pathological data for research purposes.
: The present manuscript does not contain any individual person’s data in any form.
: PGC received honoraria for speaker, consultancy or advisory role from: Bayer, Deciphera, Eisai, Eli Lilly, Nektar Therapeutics, Pfizer. His Unit received research funds from: Advenchen Laboratories, Amgen Dompé, AROG Pharmaceuticals, Bayer, Blueprint Medicines, Daiichi Sankyo, Deciphera, Eisai, Eli Lilly, Epizyme Inc, Glaxo, Karyopharm Pharmaceuticals, Novartis, Pfizer, PharmaMar. All the other authors declare no competing interests.
